Biothree

ApprovedSmall molecule

CChang Gung Memorial Hospital

Biothree is one of 5 small molecule programs targeting Enterocolitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EnterocolitisActive, not recruiting

EnterocolitisApproved

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Enterocolitis

#DrugCompanyPhaseTrials

Rocephin

CConrado Roberto Hoffmann Filho

Approved

1 2

Vancocin

HHikma Pharmaceuticals LLC

Approved

—3

Biothree

CChang Gung Memorial Hospital

Approved

1 4

VSL#3

CCD Pharma India Pvt. Ltd.

Phase 2

1 5

High-Dose Chemotherapy

EEastern Cooperative Oncology Group

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Enterocolitis1 trial

Effect of Probiotics (Bio-Three) in Children's Enterocolitis

Completed·—·Phase 4·NCT00463190·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Biothree. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biothree compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biothree. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chang Gung Memorial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CChang Gung Memorial Hospital

Biothree

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Enterocolitis1 trial

References

Drug Info

Quick Facts

Related News